OncoMatch/Clinical Trials/Sonrotoclax
Sonrotoclax (BGB-11417) Clinical Trials
Sonrotoclax (BGB-11417) is a potent, highly selective BCL-2 inhibitor developed by BeiGene with binding affinity reported to exceed that of venetoclax in preclinical studies. It is being evaluated primarily in combination with the BTK inhibitor zanubrutinib across B-cell malignancies, with the CELESTIAL-RRMCL Phase 3 trial investigating this combination versus investigator's choice in relapsed/refractory mantle cell lymphoma. Additional trials span CLL, AML, MDS, and multiple myeloma. Eligibility criteria vary by indication; MCL trials typically require 1–3 prior lines including a BTK inhibitor, while CLL trials may specify 17p deletion, TP53 mutation, or prior venetoclax exposure.
Check your eligibilityRecruiting Sonrotoclax trials
Ranked by phase and US site count. Filter by your biomarker profile →
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Christine Ryan
More Sonrotoclax trials
How OncoMatch helps you find Sonrotoclax trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Sonrotoclax trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.